
The Path to Helping Protect against Childhood Vaccine-Preventable Disease




We introduced a pneumococcal conjugate vaccine in developing countries in 2010, just one year after its introduction in mature markets, a process that usually takes between 10 and 15 years.




Through our partnership with Gavi, we have helped more than 45 eligible countries introduce a pneumococcal conjugate vaccine into their immunization programs.





Implementation of 2D barcodes on secondary and tertiary packaging was shown in a recent Nicaraguan pilot to reduce transaction time by **68%** - from **1 minute to 18 seconds** ensuring accuracy in scanning and helping to move and administer doses more efficiently. We are conducting **"train the trainer"** sessions in **19 countries in 2017** to help central and regional immunization teams, reaching between **200** and **500** health care workers in each country.

## More Doses, Less Cold Chain:



In 2017, Pfizer will introduce a **multi-dose vial (MDV)** presentation of a pneumococcal conjugate vaccine to Gavi countries. With the resulting **75%** reduction in cold chain and shipping material requirements, vaccinators will be able to accommodate **7,200** doses in the same amount of space that previously housed just **1,800 doses**.

## Sustainable Investments:



We have been able to once again reduce the price of pneumococcal conjugate vaccines. **Each MDV dose now costs just \$3.05, down 13% from our original commitment tail price of \$3.50.** This price is available to Gavi eligible and Gavi transitioned countries until 2025, allowing us to help protect children in over 45 Gavi countries.

